June 25, 2014 | The biotechnology company MacroCure reportedly will file for a Nasdaq public offering to raise several tens of millions of dollars on Wall Street. According to a “Globes” report, the IPO is being underwritten by Credit Suisse Group, Jefferies LLC, Oppenheimer & Co and Nomura Securities International. MacroCure, based in Petah Tikvah, has developed a method for treating wounds using white blood cells taken from donor blood. According to the company, their Curexell treatment showed a 90 percent reduction rate in patients with deep wound infections.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Israeli Startup Rings Closing Bell At Nasdaq in NYC
March 28, 2024
Israeli, US Companies Unite To Make More Milk From Mushrooms
March 27, 2024
Facebook comments